Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia

Acta Haematologica

Volumn 127, Issue 2, 2012, Pages 115-117

  Dujmovic, Dino ^a   Aurer, Igor ^a,b   Radman, Ivo ^a   Serventi Seiwerth, Ranka ^a   Dotlic, Snjezana ^a   Stern Padovan, Ranka ^a   Dubravcic, Klara ^a   Santek, Fedor ^a   Labar, Boris ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR CELL DESTRUCTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC PROTOCOLS; BURKITT LYMPHOMA; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84855167200     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000334705     Document Type: Article

References (12)

1. Yustein IT, Dang CV: Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol 2007; 14: 375-381. (Pubitemid 46842812)
2. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Loffler H, Fonatsch C, Rieder H, Heil G, Heinze B, Arnold R, Hossfeld D, Buchner T, Koch P, Freund M, Hiddemann W, Maschmeyer G, Heyll A, Aul C, Faak T, Kuse R, Ittel TH, Gramatzki M, Diedrich H, Kolbe K, Fuhr HG, Fischer K, Schadeck-Gressel C, Weiss A, Strohscheer I, Metzner B, Fabry U, Gokbuget N, Volkers B, Messerer D, Uberla K: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508. (Pubitemid 26030305)
3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Mueller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392. (Pubitemid 24273002)
4. Diebold J, Jaffe ES, Raphael M, Warnke RA: Burkitt lymphoma; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2001, pp 181-187.
5. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM: Burkitt lymphoma; in Swerdlow SH, Campo E, Herris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2008, pp 262-264.
6. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569-1580.
7. Hoelzer D: Recent results in the treatment of Burkitt lymphomas (abstract 8). Ann Oncol 2008; 19(suppl 4):83.
8. Oriol A, Ribera JM, Bergua J, Gimenez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D: High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008; 113: 117-125. (Pubitemid 351976392)
9. Grisekvicius L, Stulpinas R, Saulyte-Trakymiene S, Mickys U, Pranys D, Kurtinaitis J, Jurgutis M: Favorable outcome with chemoimmunotherapy in Burkitt lymphoma and leukemia. Leuk Res 2009; 33: 587-588.
10. Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Powell BL, Shea TC, Nattom S, Hoke E, Cheson BD, Larson R: Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002 (abstract 858). Blood 2010; 116: 374.
11. Barnes JA, LaCasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS: Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt-s lymphoma: a retrospective analysis. Ann Oncol 2011; 22: 1859-1864.
12. Nagasaki A, Yamanoha A, Okudaira T, Miyagi T, Takasu N: Treatment-related Burkitt's lymphoma: literature review and case report of successful treatment with rituximab. Acta Haematol 2009; 122: 211-215.